Reviewing Northwest Biotherapeutics (OTCMKTS:NWBO) and NeuroBo Pharmaceuticals (NASDAQ:NRBO)

NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Northwest Biotherapeutics (OTCMKTS:NWBO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Valuation & Earnings

This table compares NeuroBo Pharmaceuticals and Northwest Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A
Northwest Biotherapeutics	$1.93 million	186.61	-$62.60 million	($0.08)	-3.38

NeuroBo Pharmaceuticals has higher earnings, but lower revenue than Northwest Biotherapeutics.

Risk and Volatility

NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Northwest Biotherapeutics has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for NeuroBo Pharmaceuticals and Northwest Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroBo Pharmaceuticals	0	0	1	0	3.00
Northwest Biotherapeutics	0	0	0	0	0.00

NeuroBo Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 405.05%. Given NeuroBo Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe NeuroBo Pharmaceuticals is more favorable than Northwest Biotherapeutics.

Profitability

This table compares NeuroBo Pharmaceuticals and Northwest Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%
Northwest Biotherapeutics	-4,666.29%	N/A	-261.36%

Institutional and Insider Ownership

1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are owned by company insiders. Comparatively, 8.7% of Northwest Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

NeuroBo Pharmaceuticals beats Northwest Biotherapeutics on 8 of the 11 factors compared between the two stocks.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.